Short Interest in Immune Design Corp (IMDZ) Expands By 86.6%

Immune Design Corp (NASDAQ:IMDZ) saw a large growth in short interest in November. As of November 15th, there was short interest totalling 1,348,299 shares, a growth of 86.6% from the October 31st total of 722,704 shares. Approximately 5.2% of the shares of the company are short sold. Based on an average daily trading volume, of 1,177,872 shares, the days-to-cover ratio is currently 1.1 days.

Several research analysts have issued reports on IMDZ shares. Wells Fargo & Company cut Immune Design from an “outperform” rating to a “market perform” rating and dropped their target price for the stock from $29.00 to $10.00 in a research report on Tuesday, October 17th. ValuEngine cut Immune Design from a “sell” rating to a “strong sell” rating in a research report on Saturday, October 21st. Zacks Investment Research raised Immune Design from a “hold” rating to a “buy” rating and set a $4.75 target price on the stock in a research report on Monday, November 6th. Royal Bank Of Canada started coverage on Immune Design in a research report on Thursday, September 14th. They issued an “outperform” rating and a $20.00 target price on the stock. Finally, BidaskClub cut Immune Design from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 5th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $13.19.

Immune Design (NASDAQ IMDZ) opened at $4.00 on Wednesday. Immune Design has a 12-month low of $3.78 and a 12-month high of $13.05.

Immune Design (NASDAQ:IMDZ) last announced its earnings results on Wednesday, November 1st. The biotechnology company reported ($0.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.63) by $0.11. The business had revenue of $0.52 million for the quarter, compared to analysts’ expectations of $0.62 million. Immune Design had a negative return on equity of 68.69% and a negative net margin of 619.62%. sell-side analysts predict that Immune Design will post -1.89 EPS for the current fiscal year.

In other Immune Design news, Director Peter Svennilson acquired 2,681,000 shares of Immune Design stock in a transaction that occurred on Friday, October 27th. The stock was bought at an average cost of $4.10 per share, for a total transaction of $10,992,100.00. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. Also, major shareholder Leo Guthart acquired 2,439,000 shares of Immune Design stock in a transaction that occurred on Friday, October 27th. The stock was acquired at an average price of $4.10 per share, with a total value of $9,999,900.00. The disclosure for this purchase can be found here. Insiders purchased a total of 5,300,000 shares of company stock valued at $21,874,900 over the last quarter. 20.70% of the stock is owned by corporate insiders.

Several hedge funds have recently bought and sold shares of IMDZ. FMR LLC lifted its position in shares of Immune Design by 0.4% during the 1st quarter. FMR LLC now owns 445,152 shares of the biotechnology company’s stock valued at $3,027,000 after buying an additional 1,699 shares in the last quarter. TIAA CREF Investment Management LLC lifted its position in shares of Immune Design by 18.9% during the 1st quarter. TIAA CREF Investment Management LLC now owns 45,574 shares of the biotechnology company’s stock valued at $310,000 after buying an additional 7,236 shares in the last quarter. Renaissance Technologies LLC lifted its position in shares of Immune Design by 170.0% during the 1st quarter. Renaissance Technologies LLC now owns 111,740 shares of the biotechnology company’s stock valued at $760,000 after buying an additional 70,351 shares in the last quarter. Bank of America Corp DE lifted its position in shares of Immune Design by 123.3% during the 1st quarter. Bank of America Corp DE now owns 15,246 shares of the biotechnology company’s stock valued at $104,000 after buying an additional 8,418 shares in the last quarter. Finally, Trexquant Investment LP lifted its position in shares of Immune Design by 15.5% during the 2nd quarter. Trexquant Investment LP now owns 31,152 shares of the biotechnology company’s stock valued at $304,000 after buying an additional 4,174 shares in the last quarter. 29.38% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: “Short Interest in Immune Design Corp (IMDZ) Expands By 86.6%” was originally published by Transcript Daily and is the property of of Transcript Daily. If you are viewing this news story on another site, it was illegally copied and republished in violation of US & international copyright and trademark laws. The original version of this news story can be viewed at https://transcriptdaily.com/2017/11/29/short-interest-in-immune-design-corp-imdz-expands-by-86-6.html.

Immune Design Company Profile

Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.

Receive News & Ratings for Immune Design Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design Corp and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply